SSII SS Innovations International, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1676163 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY27.3%
TTM net income YoY15.5%
TTM EPS YoY-16.7%
Revenue 3-yr CAGR104.7%
Net income 3-yr CAGR—
Margins
Gross margin47.7%
Operating margin-27.7%
Net margin-31.5%
FCF margin—
EBITDA margin-24.8%
Returns
ROE-32.3%
ROA-17.4%
ROIC (approx.)-28.4%
Asset turnover0.55x
Leverage & solvency
Liabilities / assets48.3%
Debt / equity0.03x
Current ratio2.10x
Interest coverage-8.95x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $6.33M | $13.94M | $11.10M | $14.53M | $12.83M | $10.00M | $5.12M | $8.12M |
| Cost of revenue | $3.22M | $6.84M | $5.77M | $8.16M | $6.66M | $4.09M | $4.03M | $2.59M |
| Gross profit | $3.11M | $7.10M | $5.33M | $6.38M | $6.16M | $5.92M | $1.09M | $3.03M |
| R&D expense | $2.50M | $2.40M | $995,440 | $1.39M | $786,319 | $498,600 | $1.01M | $765,412 |
| SG&A expense | $4.15M | $4.45M | $4.50M | $3.39M | $4.82M | $3.43M | $3.41M | $2.74M |
| Operating income | -$6.06M | -$2.27M | -$3.64M | -$734,997 | -$1.84M | $97,014 | -$5.92M | -$7.63M |
| Interest expense | $454,549 | $344,761 | $284,051 | $335,296 | $176,636 | $216,800 | $379,905 | $292,954 |
| Pretax income | -$5.95M | -$2.16M | -$3.43M | -$705,727 | -$1.87M | $97,038 | -$5.68M | -$1.92M |
| Income tax | -$204,259 | $505,276 | $151,352 | $1.77M | $1.85M | $353,729 | — | — |
| Net income | -$5.75M | -$2.66M | -$3.58M | -$2.47M | -$3.72M | -$256,691 | -$5.68M | -$7.45M |
| EBITDA | -$5.70M | -$1.92M | -$3.32M | -$425,506 | -$1.54M | $357,375 | -$5.71M | -$7.46M |
| EPS (basic) | -0.03 | -0.01 | -0.02 | — | -0.02 | 0.00 | -0.03 | — |
| EPS (diluted) | -0.03 | -0.01 | -0.02 | — | -0.02 | 0.00 | -0.03 | — |
| Weighted avg. shares (diluted) | 209.65M | 209.42M | 205.31M | — | 202.86M | 202.84M | 188.60M | — |
| Banking | ||||||||
| Net interest income | $299,701 | $263,097 | $261,878 | $206,796 | $140,415 | $71,102 | $79,236 | $85,276 |
| Deposits | $1.71M | — | $543,347 | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.11M | $13.65M | $15.98M | $3.21M | $12.04M | $17.61M | $22.08M | $6.62M |
| Receivables | $16.76M | $16.99M | $14.05M | $12.40M | $6.92M | $5.97M | $3.96M | $4.47M |
| Inventory | $22.07M | $18.48M | $17.07M | $17.06M | $20.04M | $18.26M | $14.30M | $10.21M |
| Current assets | $70.63M | $71.45M | $66.26M | $48.77M | $48.42M | $50.79M | $47.62M | $27.42M |
| PP&E, net | $9.76M | $8.64M | $8.83M | $9.10M | $8.25M | $8.27M | $7.04M | $5.39M |
| Total assets | $96.51M | $96.98M | $90.55M | $74.23M | $69.58M | $69.98M | $63.46M | $42.39M |
| Current liabilities | $33.70M | $31.89M | $26.05M | $26.24M | $21.19M | $19.61M | $15.00M | $21.33M |
| Short-term debt | $52,136 | — | — | $11.44M | — | — | — | — |
| Long-term debt | $1.20M | — | — | — | — | — | — | — |
| Total debt | $1.25M | — | — | — | — | — | — | — |
| Total liabilities | $46.57M | $43.58M | $36.02M | $36.01M | $29.93M | $27.95M | $22.90M | $28.93M |
| Shareholders' equity | $49.94M | $53.37M | $54.52M | $38.22M | $39.65M | $42.02M | $40.55M | $13.46M |
| Net debt | -$6.86M | — | — | — | — | — | — | — |
| Shares outstanding | 200.49M | 200.17M | 200.13M | 194.17M | 193.59M | 193.59M | 193.56M | 171.58M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.37M | -$4.23M | -$2.31M | -$1.52M | -$7.47M | -$3.45M | -$6.10M | -$4.03M |
| Capital expenditure | — | — | $54,189 | $1.71M | $755,075 | $316,648 | $872,804 | -$976,199 |
| Free cash flow | — | — | -$2.37M | -$3.23M | -$8.22M | -$3.77M | -$6.98M | -$3.05M |
| Investing cash flow | -$1.49M | -$160,871 | -$54,189 | -$1.71M | -$755,075 | -$316,648 | -$872,804 | $994,016 |
| Financing cash flow | $3.50M | $3.48M | $18.16M | $1.37M | $3.09M | -$702,098 | $22.41M | $3.41M |
| Depreciation & amortization | $359,249 | $346,364 | $323,747 | $309,491 | $297,173 | $260,361 | $208,882 | $169,721 |
| Stock-based compensation | $2.15M | $2.18M | $3.14M | $2.02M | $2.10M | $1.63M | $2.38M | $7.76M |
Free plan shows the latest 8 periods; Pro shows all 42 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.